18 November 2014
EMA/COMP/641491/2014
Committee for Orphan Medicinal Products (COMP)

Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation

November 2014

The Committee for Orphan Medicinal Products held its 161st plenary meeting on 11-13 November 2014.

Orphan medicinal product designation

Positive opinions

The COMP adopted 27 positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission (EC):

1. Opinions adopted at the second COMP discussion, following the sponsor's response to the COMP list of questions:

- Adeno-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA for treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome); LYSOGENE
- Allogeneic bone marrow derived mesenchymal cells expanded ex vivo in synthetic media for prevention of graft-versus-host disease; Cell2B Advanced Therapeutics, SA
- Exisulind for treatment of familial cerebral cavernous malformations; Firc Institute of Molecular Oncology (IFOM)
- Heat-killed *Mycobacterium obuense* (whole cell) for treatment of pancreatic cancer; Immodulon Therapeutics Ltd
- Single-chain urokinase plasminogen activator for treatment of pleural empyema; Coté Orphan Consulting UK Limited

2. Opinions adopted at the first COMP discussion:

- ((E)-1-(4'-chlorophenyl)-3-(4-hydroxy-3-metoxyphenyl)prop-2-en-1-one) for treatment of WHIM syndrome; Centre National de la Recherche Scientifique (CNRS)
- (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine for treatment of neurotrophic keratitis; MIMETECH S.r.l.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

- 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one for treatment of multiple system atrophy; AstraZeneca AB
- 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one for treatment of ovarian cancer; Aprea AB
- 5,5'-(4-(trifluromethyl)benzylazanediyl)bis(methylene)diquinolin-8-ol for treatment of glioma; Prof. Olivier Blin
- 5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine for treatment of malignant mesothelioma; TMC Pharma Services Ltd
- 5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl) pyrimidine-4,6-diamine for treatment of Huntington's disease; Palobiofarma S.L.
- Adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain for treatment of glioma; Alan Boyd Consultants Ltd
- Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist for treatment of acute lymphoblastic leukaemia; Novartis Europharm Limited
- Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells for treatment of acute myeloid leukaemia; IPD-Therapeutics BV
- Allogeneic adipose-derived adult mesenchymal stem cells contained in a fibrin-based bioengineered dermis for treatment of epidermolysis bullosa; Biodan Yelah S.L.
- Amikacin sulfate for treatment of *Pseudomonas aeuriginosa* lung infections in cystic fibrosis; PlumeStars s.r.l.
- Autologous collagen type II-specific regulatory T cells for treatment of non-infectious uveitis; TxCell
- Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor for treatment of diffuse large B cell lymphoma; Kite Pharma UK, Ltd
- Benserazide hydrochloride for treatment of beta-thalassaemia intermedia and major; Isabelle Ramirez
- Bevacizumab for treatment of hereditary haemorrhagic telangiectasia; Dr Sophie Dupuis-Girod
- Chenodeoxycholic acid for treatment of inborn errors in primary bile acid synthesis; Sigma-Tau Pharma Ltd
- Edaravone for treatment of amyotrophic lateral sclerosis; Treeway B.V.
- Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for treatment of malignant mesothelioma; Oncos Therapeutics Oy
- Pegylated recombinant human hyaluronidase PH20 for treatment of pancreatic cancer; Pharm. Research Associates (UK) Limited
- Plerixafor for treatment of WHIM syndrome; Groupe d'étude des neutropénies
- Riluzole for treatment of traumatic spinal cord injury; Dr Laurent Vinay

Negative opinion

Further to expiry of the deadline for appeal, the COMP confirmed 1 negative opinion adopted on 21 July 2014 recommending the refusal of the orphan medicinal product designation for the following product:

- Sodium ascorbate and menadione sodium bisulfite for treatment of autosomal dominant polycystic kidney disease; JJGConsultancy Ltd

Public summaries of opinions will be available on the EMA website following adoption of the respective decisions on orphan designation[1] by the European Commission.

Lists of questions

The COMP adopted 22 lists of questions on initial applications. These applications will be discussed again at the next COMP meeting prior to the adoption of an opinion.

Oral hearings

8 oral hearings took place.

Withdrawals of applications for orphan medicinal product designation

The COMP noted that 5 applications for orphan medicinal product designation were withdrawn.

Detailed information on the orphan designation procedures

An overview of orphan designation procedures since 2000 is provided in Annex 1.

The list of medicinal products for which decisions on orphan designation have been given by the European Commission since the last COMP meeting is provided in Annex 2.

Applications for marketing authorisation for orphan medicinal products

Details of those designated orphan medicinal products that have been subject of a new European Union (EU) marketing authorisation application through the centralised procedure since the last COMP plenary meeting are provided in Annex 3.

Details on the authorised orphan medicinal products can be found on the EMA website.

Article 5(12) (b) of Regulation (EC) No 141/2000 of the European Parliament and of the Council

In line with its responsibility to review whether or not a designated orphan medicinal product still fulfils the designation criteria prior to the granting of a marketing authorisation, the COMP adopted 3 opinions recommending to the European Commission that the following orphan medicinal product be kept in the EU registry of orphan medicinal product:

- Cyramza (ramucirumab) for treatment of gastric cancer; Eli Lilly Nederland B.V. (EU/3/12/1004)

[1] Details of all orphan designations granted to date by the European Commission are entered in the EU Register of Orphan Medicinal Products

- Lynparza (olaparib) for treatment of ovarian cancer; AstraZeneca AB (EU/3/07/501)
- Scenesse ([Nle4, D-Phe7]-alfa-melanocyte stimulating hormone) for treatment of erythropoietic protoporphyria; Clinuvel (UK) Limited (EU/3/08/541)

Other matters

The main topics addressed during the meeting related to:

- Protocol assistance advice

Upcoming meetings

- The 162nd meeting of the COMP will be held on 9-11 December 2014

Note

This monthly report, together with other information on the work of the European Medicines Agency, can be found on the EMA website: www.ema.europa.eu

Contact our press officer

Monika Benstetter

Tel. +44 (0)20 3660 8427, E-mail: press@ema.europa.eu

Annex 1

Overview for orphan medicinal product designation procedure since 2000

Year	Applications submitted	Applications discussed in reporting year	Positive COMP opinions	Applications withdrawn	Final negative COMP opinions	EC designations	Orphan medicinal products[2] authorised	Orphan designations included in authorised therapeutic indication
2014	273	226	175 (77%)	49 (22%)	2 (1%)	131	11	12
2013	201	197	136 (69%)	60 (30%)	1 (1%)	136	7	8
2012	197	192	139 (72%)	52 (27%)	1 (1%)	148	10	12
2011	166	158	111 (70%)	45 (29%)	2 (1%)	107	5	5
2010	174	176	123 (70%)	51 (29%)	2 (1%)	128	4	4
2009	164	136	113 (83%)	23 (17%)	0 (0%)	106	9	9
2008	119	118	86 (73%)	31 (26%)	1 (1%)	73	6	7
2007	125	117	97 (83%)	19 (16%)	1 (1%)	98	13	13
2006	104	103	81 (79%)	20 (19%)	2 (2%)	80	9	11
2005	118	118	88 (75%)	30 (25%)	0 (0%)	88	4	4
2004	108	101	75 (74%)	22 (22%)	4 (4%)	73	6	6
2003	87	96	54 (56%)	41 (43%)	1 (1%)	55	5	5
2002	80	75	43 (57%)	30 (40%)	2 (3%)	49	4	4
2001	83	90	62 (70%)	27 (29%)	1 (1%)	64	3	3
2000	72	32	26 (81%)	6 (19%)	0 (0%)	14	0	0
Total	**2071**	**1935**	**1409 (73%)**	**506 (26%)**	**20 (1%)**	**1350**	**96**	**103**

[2] Number of authorised orphan medicinal products may cover more than one orphan designation

Annex 2

Medicinal products granted a European Union designation as orphan medicinal product by the European Commission since the October 2014 COMP monthly report

Active substance	Orphan indication	Sponsor	COMP opinion date	EC designation date
(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	Treatment of fragile X syndrome	Centre National de la Recherche Scientifique (CNRS)	4 September 2014	15 October 2014
(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile	Treatment of pemphigus	Almirall S.A.	4 September 2014	15 October 2014
(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride	Treatment of Leigh syndrome	Khondrion BV	4 September 2014	15 October 2014
Acamprosate calcium	Treatment of fragile X syndrome	Real Regulatory Limited	4 September 2014	15 October 2014
Adeno-associated viral vector serotype 8 containing the human *UGT1A1* gene	Treatment of Crigler-Najjar syndrome	Généthon	4 September 2014	15 October 2014
Cannabidiol	Treatment of Dravet syndrome	GW Pharma Ltd	4 September 2014	15 October 2014
Cultured allogeneic corneal limbal stem cells	Treatment of limbal stem cell deficiency	NHS National Services Scotland Trading as Scottish National Blood Transfusion Service	4 September 2014	15 October 2014
Cysteamine hydrochloride	Treatment of cystinosis	Lucane Pharma SA	4 September 2014	15 October 2014
Glucagon	Treatment of congenital hyperinsulinism	S-cubed Limited	4 September 2014	15 October 2014

Active substance	Orphan indication	Sponsor	COMP opinion date	EC designation date
Immunoglobulin G1, anti-(human tumour-associated calcium signal transducer 2)(human-Mus musculus monoclonal hRS7 heavy chain), disulfide with human-Mus musculus monoclonal hRS7 κ-chain, dimer, hexakis(thioether) with (4S)-4-[[[[4-[[(2S)-2-(4-aminobutyl)-2-[[2-[2-[[26-[4-[[[[4-[(3-mercapto-2,5-dioxo-1-pyrrolidinyl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-3,6,9,12,15,18,21,24-octaoxahexacos-1-yl]amino]-2-oxoethoxy]acetyl]amino]-1-oxoethyl]amino]phenyl]methoxy]carbonyl]oxy]-4,11-diethyl-9-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	Treatment of pancreatic cancer	Immunomedics GmbH	4 September 2014	15 October 2014
Nitric oxide	Treatment of cystic fibrosis	PD Dr.med. Joachim Riethmüller	4 September 2014	15 October 2014
Osilodrostat	Treatment of Cushing's syndrome	Novartis Europharm Limited	4 September 2014	15 October 2014
Oxalobacter formigenes strain HC-1	Treatment of short bowel syndrome	OxThera AB	4 September 2014	15 October 2014
Pyridoxal 5'-phosphate	Treatment of pyridoxamine 5'-phosphate oxidase deficiency	Great Ormond Street Hospital for Children, NHS Foundation Trust	4 September 2014	15 October 2014
Recombinant human bone morphogenetic protein 4	Treatment of glioma	STEMGEN S.p.A	4 September 2014	15 October 2014
Recombinant human insulin receptor monoclonal antibody-fused-α-L-iduronidase	Treatment of mucopolysaccharidosis type I	Voisin Consulting S.A.R.L.	4 September 2014	15 October 2014

Active substance	Orphan indication	Sponsor	COMP opinion date	EC designation date
Recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	Treatment of tenosynovial giant cell tumour, localised and diffused type	Novartis Europharm Limited	4 September 2014	15 October 2014
Recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23	Treatment of X-linked hypophosphataemia	NDA Group AB	4 September 2014	15 October 2014
Raxibacumab	Treatment of inhalation anthrax disease	GlaxoSmithKline Trading Services Limited	4 September 2014	15 October 2014

Annex 3

Designated orphan medicinal products that have been subject of a new European Union marketing authorisation application under the centralised procedure since the October 2014 COMP monthly report

Active substance	Designated orphan indication	Sponsor/applicant	EU designation number
Blinatumomab	Treatment of acute lymphoblastic leukaemia	Amgen Europe B.V.	EU/3/09/650
Efmoroctocog alfa	Treatment of haemophilia A	Biogen Idec Ltd	EU/3/10/783